Sensitizing human colon carcinoma HT-29 cells to cisplatin by cyclopentenylcytosine, in vitro and in vivo

Kamran Gharehbaghi, Thomas Szekeres, Joel A. Yalowitz, Monika Fritzer-Szekeres, Yves G. Pommier, Hiremagalur N. Jayaram

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Cyclopentenylcytosine (CPEC) is cytotoxic to HT-29 cells in vitro and in vivo. Treatment with CPEC resulted in sensitizing HT-29 cells to cisplatin (CDDP), as evidenced by synergistic cytotoxicity. CPEC exhibits potent cytotoxicity to HT-29 cells in vitro, 2 and 24 h exposure providing an LC50 of 2.4 and 0.46 μM, respectively. Exposure of HT-29 cells to CDDP for 2 h resulted in an LC50 of 26 μM. Treatment of HT-29 cells with 1,0 or 1.25 μm CPEC and then incubating with CDDP showed synergistic cytotoxicity. Lesser synergy at very high concentrations of CPEC was demonstrated when HT-29 cells were first exposed to CDDP and then incubatedwith CPEC. Combination index calculations showed synergistic cytotoxicity in HT-29 cells when CPEC was combined with CDDP. Synergistic antitumor activity was demonstrable in vivo in mice transplanted with HT-29 tumor when treated with a combination of CPEC and CDDP without undue toxicity, since no excessive loss in mouse body weight or overt pathology was observed. CPEC had no influence on the total DNA adduct formation and CDDP did not affect the intracellular levels of CPEC or its metabolites, suggesting that enhanced CDDP cytotoxicity resulted from a step subsequent to excision of platinum-cross-linked DNA. These studies support a new approach for augmenting cytotoxic effect of CPEC with CDDP in treating human colon carcinoma. (C) 2000 Elsevier Science Inc.

Original languageEnglish
Pages (from-to)1-11
Number of pages11
JournalLife Sciences
Volume68
Issue number1
DOIs
StatePublished - Nov 24 2000

Fingerprint

cyclopentenyl cytosine
HT29 Cells
Cisplatin
Colon
Carcinoma
Cytotoxicity
In Vitro Techniques

Keywords

  • Antitumor activity
  • Cisplatin, synergy
  • Cyclopentenylcytosine
  • Human colon carcinoma HT-29

ASJC Scopus subject areas

  • Pharmacology

Cite this

Gharehbaghi, K., Szekeres, T., Yalowitz, J. A., Fritzer-Szekeres, M., Pommier, Y. G., & Jayaram, H. N. (2000). Sensitizing human colon carcinoma HT-29 cells to cisplatin by cyclopentenylcytosine, in vitro and in vivo. Life Sciences, 68(1), 1-11. https://doi.org/10.1016/S0024-3205(00)00914-0

Sensitizing human colon carcinoma HT-29 cells to cisplatin by cyclopentenylcytosine, in vitro and in vivo. / Gharehbaghi, Kamran; Szekeres, Thomas; Yalowitz, Joel A.; Fritzer-Szekeres, Monika; Pommier, Yves G.; Jayaram, Hiremagalur N.

In: Life Sciences, Vol. 68, No. 1, 24.11.2000, p. 1-11.

Research output: Contribution to journalArticle

Gharehbaghi, K, Szekeres, T, Yalowitz, JA, Fritzer-Szekeres, M, Pommier, YG & Jayaram, HN 2000, 'Sensitizing human colon carcinoma HT-29 cells to cisplatin by cyclopentenylcytosine, in vitro and in vivo', Life Sciences, vol. 68, no. 1, pp. 1-11. https://doi.org/10.1016/S0024-3205(00)00914-0
Gharehbaghi K, Szekeres T, Yalowitz JA, Fritzer-Szekeres M, Pommier YG, Jayaram HN. Sensitizing human colon carcinoma HT-29 cells to cisplatin by cyclopentenylcytosine, in vitro and in vivo. Life Sciences. 2000 Nov 24;68(1):1-11. https://doi.org/10.1016/S0024-3205(00)00914-0
Gharehbaghi, Kamran ; Szekeres, Thomas ; Yalowitz, Joel A. ; Fritzer-Szekeres, Monika ; Pommier, Yves G. ; Jayaram, Hiremagalur N. / Sensitizing human colon carcinoma HT-29 cells to cisplatin by cyclopentenylcytosine, in vitro and in vivo. In: Life Sciences. 2000 ; Vol. 68, No. 1. pp. 1-11.
@article{d4bf08a691604f1d9c2cf5e0855e2a23,
title = "Sensitizing human colon carcinoma HT-29 cells to cisplatin by cyclopentenylcytosine, in vitro and in vivo",
abstract = "Cyclopentenylcytosine (CPEC) is cytotoxic to HT-29 cells in vitro and in vivo. Treatment with CPEC resulted in sensitizing HT-29 cells to cisplatin (CDDP), as evidenced by synergistic cytotoxicity. CPEC exhibits potent cytotoxicity to HT-29 cells in vitro, 2 and 24 h exposure providing an LC50 of 2.4 and 0.46 μM, respectively. Exposure of HT-29 cells to CDDP for 2 h resulted in an LC50 of 26 μM. Treatment of HT-29 cells with 1,0 or 1.25 μm CPEC and then incubating with CDDP showed synergistic cytotoxicity. Lesser synergy at very high concentrations of CPEC was demonstrated when HT-29 cells were first exposed to CDDP and then incubatedwith CPEC. Combination index calculations showed synergistic cytotoxicity in HT-29 cells when CPEC was combined with CDDP. Synergistic antitumor activity was demonstrable in vivo in mice transplanted with HT-29 tumor when treated with a combination of CPEC and CDDP without undue toxicity, since no excessive loss in mouse body weight or overt pathology was observed. CPEC had no influence on the total DNA adduct formation and CDDP did not affect the intracellular levels of CPEC or its metabolites, suggesting that enhanced CDDP cytotoxicity resulted from a step subsequent to excision of platinum-cross-linked DNA. These studies support a new approach for augmenting cytotoxic effect of CPEC with CDDP in treating human colon carcinoma. (C) 2000 Elsevier Science Inc.",
keywords = "Antitumor activity, Cisplatin, synergy, Cyclopentenylcytosine, Human colon carcinoma HT-29",
author = "Kamran Gharehbaghi and Thomas Szekeres and Yalowitz, {Joel A.} and Monika Fritzer-Szekeres and Pommier, {Yves G.} and Jayaram, {Hiremagalur N.}",
year = "2000",
month = "11",
day = "24",
doi = "10.1016/S0024-3205(00)00914-0",
language = "English",
volume = "68",
pages = "1--11",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Sensitizing human colon carcinoma HT-29 cells to cisplatin by cyclopentenylcytosine, in vitro and in vivo

AU - Gharehbaghi, Kamran

AU - Szekeres, Thomas

AU - Yalowitz, Joel A.

AU - Fritzer-Szekeres, Monika

AU - Pommier, Yves G.

AU - Jayaram, Hiremagalur N.

PY - 2000/11/24

Y1 - 2000/11/24

N2 - Cyclopentenylcytosine (CPEC) is cytotoxic to HT-29 cells in vitro and in vivo. Treatment with CPEC resulted in sensitizing HT-29 cells to cisplatin (CDDP), as evidenced by synergistic cytotoxicity. CPEC exhibits potent cytotoxicity to HT-29 cells in vitro, 2 and 24 h exposure providing an LC50 of 2.4 and 0.46 μM, respectively. Exposure of HT-29 cells to CDDP for 2 h resulted in an LC50 of 26 μM. Treatment of HT-29 cells with 1,0 or 1.25 μm CPEC and then incubating with CDDP showed synergistic cytotoxicity. Lesser synergy at very high concentrations of CPEC was demonstrated when HT-29 cells were first exposed to CDDP and then incubatedwith CPEC. Combination index calculations showed synergistic cytotoxicity in HT-29 cells when CPEC was combined with CDDP. Synergistic antitumor activity was demonstrable in vivo in mice transplanted with HT-29 tumor when treated with a combination of CPEC and CDDP without undue toxicity, since no excessive loss in mouse body weight or overt pathology was observed. CPEC had no influence on the total DNA adduct formation and CDDP did not affect the intracellular levels of CPEC or its metabolites, suggesting that enhanced CDDP cytotoxicity resulted from a step subsequent to excision of platinum-cross-linked DNA. These studies support a new approach for augmenting cytotoxic effect of CPEC with CDDP in treating human colon carcinoma. (C) 2000 Elsevier Science Inc.

AB - Cyclopentenylcytosine (CPEC) is cytotoxic to HT-29 cells in vitro and in vivo. Treatment with CPEC resulted in sensitizing HT-29 cells to cisplatin (CDDP), as evidenced by synergistic cytotoxicity. CPEC exhibits potent cytotoxicity to HT-29 cells in vitro, 2 and 24 h exposure providing an LC50 of 2.4 and 0.46 μM, respectively. Exposure of HT-29 cells to CDDP for 2 h resulted in an LC50 of 26 μM. Treatment of HT-29 cells with 1,0 or 1.25 μm CPEC and then incubating with CDDP showed synergistic cytotoxicity. Lesser synergy at very high concentrations of CPEC was demonstrated when HT-29 cells were first exposed to CDDP and then incubatedwith CPEC. Combination index calculations showed synergistic cytotoxicity in HT-29 cells when CPEC was combined with CDDP. Synergistic antitumor activity was demonstrable in vivo in mice transplanted with HT-29 tumor when treated with a combination of CPEC and CDDP without undue toxicity, since no excessive loss in mouse body weight or overt pathology was observed. CPEC had no influence on the total DNA adduct formation and CDDP did not affect the intracellular levels of CPEC or its metabolites, suggesting that enhanced CDDP cytotoxicity resulted from a step subsequent to excision of platinum-cross-linked DNA. These studies support a new approach for augmenting cytotoxic effect of CPEC with CDDP in treating human colon carcinoma. (C) 2000 Elsevier Science Inc.

KW - Antitumor activity

KW - Cisplatin, synergy

KW - Cyclopentenylcytosine

KW - Human colon carcinoma HT-29

UR - http://www.scopus.com/inward/record.url?scp=0034711431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034711431&partnerID=8YFLogxK

U2 - 10.1016/S0024-3205(00)00914-0

DO - 10.1016/S0024-3205(00)00914-0

M3 - Article

VL - 68

SP - 1

EP - 11

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 1

ER -